Vaccinex, Inc. Announces Reverse Stock Split
September 22, 2023 16:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
September 19, 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Circular Genomics Announces Partnership on Alzheimer’s Disease Biomarker Research
September 06, 2023 17:24 ET
|
Circular Genomics
Albuquerque, NM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry, has announced a partnership with leading Alzheimer’s...
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
September 06, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
August 17, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
August 15, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to be overseen by Brigham and Women’s Hospital, a founding...
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
August 10, 2023 16:05 ET
|
Athira Pharma, Inc.
Completed end of Phase 2 meeting and continued engagement with U.S. Food and Drug AdministrationAppointed Andrew Gengos as Chief Financial Officer and Chief Business OfficerMaintains strong balance...
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
July 28, 2023 07:00 ET
|
AC Immune SA
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
Greystone Helps Reimagine Gulden’s Mustard Homestead in Bay Shore, Long Island into Assisted Living & Memory Care Community with $25 Million in HUD-Insured Construction Financing
July 25, 2023 12:53 ET
|
Greystone
Greystone Closes the Only Healthcare Construction Loan Approved by HUD in the Past Year;Long Island’s South Shore Will Be Enhanced with a New, Stunning Advanced Care-Memory Community NEW YORK, July...
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease
July 17, 2023 07:00 ET
|
Athira Pharma, Inc.
New preclinical data demonstrate neuroprotective effects of fosgonimeton in models of amyloid-ß-mediated toxicity In preclinical models, ATH-1105 protects against pathologies common to amyotrophic...